CaltechAUTHORS
  A Caltech Library Service

Antibody-based protection against HIV infection by vectored immunoprophylaxis

Balazs, Alejandro B. and Chen, Joyce and Hong, Christin M. and Rao, Dinesh S. and Yang, Lili and Baltimore, David (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature, 481 (7379). pp. 81-84. ISSN 0028-0836. PMCID PMC3253190. https://resolver.caltech.edu/CaltechAUTHORS:20200427-124011394

[img] PDF - Accepted Version
See Usage Policy.

1803Kb
[img] PDF (Supplementary Figures 1-7 with legends, Supplementary Results and additional references) - Supplemental Material
See Usage Policy.

683Kb
[img] MS PowerPoint (PowerPoint slide for Fig. 1) - Supplemental Material
See Usage Policy.

596Kb
[img] MS PowerPoint (PowerPoint slide for Fig. 2) - Supplemental Material
See Usage Policy.

520Kb
[img] MS PowerPoint (PowerPoint slide for Fig. 3) - Supplemental Material
See Usage Policy.

613Kb
[img] MS PowerPoint (PowerPoint slide for Fig. 4) - Supplemental Material
See Usage Policy.

591Kb

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20200427-124011394

Abstract

Despite tremendous efforts, development of an effective vaccine against human immunodeficiency virus (HIV) has proved an elusive goal. Recently, however, numerous antibodies have been identified that are capable of neutralizing most circulating HIV strains. These antibodies all exhibit an unusually high level of somatic mutation, presumably owing to extensive affinity maturation over the course of continuous exposure to an evolving antigen. Although substantial effort has focused on the design of immunogens capable of eliciting antibodies de novo that would target similar epitopes, it remains uncertain whether a conventional vaccine will be able to elicit analogues of the existing broadly neutralizing antibodies. As an alternative to immunization, vector-mediated gene transfer could be used to engineer secretion of the existing broadly neutralizing antibodies into the circulation. Here we describe a practical implementation of this approach, which we call vectored immunoprophylaxis (VIP), which in mice induces lifelong expression of these monoclonal antibodies at high concentrations from a single intramuscular injection. This is achieved using a specialized adeno-associated virus vector optimized for the production of full-length antibody from muscle tissue. We show that humanized mice receiving VIP appear to be fully protected from HIV infection, even when challenged intravenously with very high doses of replication-competent virus. Our results suggest that successful translation of this approach to humans may produce effective prophylaxis against HIV.


Item Type:Article
Related URLs:
URLURL TypeDescription
https://doi.org/10.1038/nature10660DOIArticle
https://rdcu.be/b3OOwPublisherFree ReadCube access
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253190PubMed CentralArticle
ORCID:
AuthorORCID
Rao, Dinesh S.0000-0002-0794-9337
Baltimore, David0000-0001-8723-8190
Additional Information:© 2012 Macmillan Publishers Limited. Received 25 July 2011; Accepted 21 October 2011; Published 30 November 2011. We thank J. Wilson for AAV8-related plasmids and assistance, D. Burton for b12 and 2G12 expression plasmids, G. Nabel for 4E10, 2F5 and VRC01 expression plasmids, and the Caltech Protein Expression Center for providing purified antibodies. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3 from M. Martin, and TZM-bl cells from J. Kappes and X. Wu. We thank J. Bloom, D. Kotton, D. Majumdar, G. Mostoslavsky, R. O’Connell and A. Sigal for comments, and other members of the Baltimore laboratory for their assistance in performing this work. This project was supported by the Bill and Melinda Gates Foundation through Grand Challenges in Global Health Initiative (awarded to D.B.) Grand Challenge grant 37866 and by the National Institutes of Health (HHSN266200500035C) through a contract from the National Institute of Allergy and Infectious Disease (NIAID) and by the Joint Center for Translational Medicine. A.B.B. is supported by amfAR postdoctoral research fellowship 107756-47-RFVA. D.S.R. is supported by career development award 1K08CA133521 from the National Institutes of Health. Author Contributions: A.B.B. and D.B. conceived the study with assistance from L.Y. A.B.B. designed the experiments. A.B.B., J.C. and C.M.H. performed experiments. A.B.B., J.C. and C.M.H. analysed the data. D.S.R. performed immunohistochemistry and analysis. A.B.B. and D.B. wrote the paper with contributions from all authors. The authors declare no competing financial interests.
Funders:
Funding AgencyGrant Number
Bill and Melinda Gates Foundation37866
NIHHHSN266200500035C
Joint Center for Translational MedicineUNSPECIFIED
American Foundation for AIDS Research107756-47-RFVA
NIH1K08CA133521
Issue or Number:7379
PubMed Central ID:PMC3253190
Record Number:CaltechAUTHORS:20200427-124011394
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20200427-124011394
Official Citation:Balazs, A., Chen, J., Hong, C. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81–84 (2012). https://doi.org/10.1038/nature10660
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:102807
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:27 Apr 2020 19:58
Last Modified:27 Apr 2020 19:58

Repository Staff Only: item control page